Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Higher Risk of Kidney Function Decline With Entecavir Than Tenofovir Alafenamide in Patients With HBV Related Acute-on-chronic Liver Failure: Real-World Study

NCT05453448 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

NCT NCT05453448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05453448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Higher Risk of Kidney Function Decline With Entecavir Than Tenofovir Alafenamide in Patients With HBV Related Acute-on-chronic Liver Failure: Real-World Study
Lead sponsor
Xiangya Hospital of Central South University
Phase
Not applicable
Overall status
Completed
Start date
May 1, 2022
Completion date
May 30, 2022
Enrollment
272 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiviral drugs